Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1682
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17826091 | FLOW CELLS AND METHODS | Final Rejection | ILLUMINA, INC. |
| 18033754 | TRANSCRIPTOMICS WITH ELECTROPHYSIOLOGICAL RECORDING | Non-Final OA | President and Fellows of Harvard College |
| 17770943 | GENOME-SCALE IMAGING OF THE 3D ORGANIZATION AND TRANSCRIPTIONAL ACTIVITY OF CHROMATIN | Final Rejection | President and Fellows of Harvard College |
| 17819472 | METHOD FOR EARLY DETERMINATION OF GENDER BY MULTIPLEX PCR DETECTING FOUR GENES | Non-Final OA | King Saud University |
| 17416399 | RATIOMETRIC FLUORESCENCE CODING METHOD FOR MULTIPLEX NUCLEIC ACID AMPLIFICATION ASSAYS | Non-Final OA | The Johns Hopkins University |
| 18496492 | METHODS, COMPOSITIONS, AND SYSTEMS FOR SPATIAL ANALYSIS OF BIOLOGICAL SAMPLES | Non-Final OA | 10x Genomics, Inc. |
| 18365684 | SYSTEMS AND METHODS FOR IMMUNOFLUORESCENCE QUANTIFICATION | Non-Final OA | 10x Genomics, Inc. |
| 18033054 | METHODS FOR TREATING A SUBJECT WITH LOCAL INVASIVE BREAST CANCER BASED ON PDGFRB LEVELS | Non-Final OA | PRELUDE CORPORATION |
| 17550262 | METHODS, SYSTEMS AND COMPOSITIONS FOR NUCLEIC ACID SEQUENCING | Final Rejection | Illumina Cambridge Limited |
| 17525530 | INCORPORATION AND IMAGING MIXES | Non-Final OA | ILLUMINA CAMBRIDGE LIMITED |
| 18494528 | COMPOSITIONS AND METHODS FOR CHARACTERIZING POLYNUCLEOTIDE SEQUENCE ALTERATIONS | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18364849 | COMPETITIVE METHODS AND COMPOSITIONS FOR AMPLIFYING POLYNUCLEOTIDES | Non-Final OA | Singular Genomics Systems, Inc. |
| 17791706 | TAP63 REGULATED ONCOGENIC LONG NON-CODING RNAS | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18247474 | RAPID DIAGNOSTIC ELECTROCHEMICAL BIOSENSING TARGETED WITH ANTISENSE OLIGONUCLEOTIDES | Non-Final OA | University of Maryland, Baltimore County |
| 17751952 | SPATIAL SEQUENCING WITH MICTAG | Final Rejection | Miltenyi Biotec B.V. & Co. KG |
| 18281930 | METHODS FOR SEQUENCING NUCLEIC ACID MOLECULES WITH SEQUENTIAL BARCODES | Non-Final OA | Ultima Genomics, Inc. |
| 18252086 | RNA SENSORS AND USES THEREOF | Non-Final OA | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
| 18306286 | Visual loop-mediated isothermal amplification (LAMP) method for the rapid test of tobacco | Non-Final OA | YUNNAN TOBACCO QUALITY SUPERVISION AND TESTING STATION |
| 18019448 | METHODS AND SYSTEMS FOR CELL-FREE DNA FRAGMENT SIZE DENSITIES TO ASSESS CANCER | Final Rejection | Delfi Diagnostics, Inc. |
| 17459459 | DETECTING ELEMENTS USING SUGAR-LECTIN COUPLINGS | Final Rejection | ILLUMINA SINGAPORE PTE. LTD. |
| 17783365 | HIGH-THROUGHPUT DETECTION METHOD FOR RARE MUTATION OF GENE | Final Rejection | SUZHOU SMK GENE TECH LTD. |
| 17616279 | KIT AND METHOD FOR ANALYZING SINGLE T CELLS | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL |
| 17779439 | DETECTION AND ELIMINATION OF ABERRANT CELLS | Final Rejection | Viome Life Sciences, Inc. |
| 17771793 | HLA-H, HLA-J, HLA-L, HLA-V AND HLA-Y AS THERAPEUTIC AND DIAGNOSTIC TARGETS | Final Rejection | Intellexon GmbH |
| 17693222 | Targeted Sequence Detection by Nanopore Sensing of Synthetic Probes | Final Rejection | Nooma Bio, Inc. |
| 17631074 | TUMOUR MARKER AND USE THEREOF | Final Rejection | Lisen Imprinting Diagnostics Wuxi Co., Ltd. |
| 17628006 | DIFFERENTIATION MARKER GENE SET, METHOD, AND KIT FOR DIFFERENTIATING OR CLASSIFYING SUBTYPE OF BREAST CANCER | Non-Final OA | PUBLIC UNIVERSITY CORPORATION FUKUSHIMA MEDICAL UNIVERSITY |
| 17618239 | METHODS AND COMPOSITIONS FOR LUNG CANCER DETECTION | Final Rejection | SUZHOU HOHO HEALTH CO., LTD. |
| 17607490 | METHODS AND REAGENTS FOR NUCLEIC ACID SEQUENCING AND ASSOCIATED APPLICATIONS | Non-Final OA | TwinStrand Biosciences, Inc. |
| 17603439 | METHOD FOR DETECTING SPECIFIC NUCLEIC ACIDS IN SAMPLES | Final Rejection | GenePath Diagnostics Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy